Antonella Vallario
University of Turin
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Antonella Vallario.
Leukemia Research | 1999
Alessandra Stacchini; Michela Aragno; Antonella Vallario; Alda Alfarano; Paola Circosta; Daniela Gottardi; Alessandra Faldella; Giovanna Rege-Cambrin; Ulf Thunberg; Kenneth Nilsson; Federico Caligaris-Cappio
We report the establishment and characterization of two cell lines, MEC1 and MEC2, that grew spontaneously on two subsequent occasions from the peripheral blood (PB) of a patient with B-chronic lymphocytic leukemia (B-CLL) in prolymphocytoid transformation. The patient was EBV-seropositive, his leukemic cells were EBNA negative, but the spontaneously grown cell lines are EBNA-2 positive. In liquid culture MEC1 cells grow adherent to the vessel wall and as tiny clumps; MEC2 cells do not adhere and form large clumps. The doubling time of MEC1 is 40h and of MEC2 is 31h. Both cell lines express the same light (kappa) and heavy chains (mu, delta) as the fresh parental B-CLL cells at the same high intensity, share the expression of mature B cell markers (CD19, CD20, CD21, CD22), differ in the expression of CD23 and FMC7, are CD11a+, CD18+, CD44+, CD49d+, CD54+ and express at high levels both CD80 and CD86. CD5 is negative on MEC1 cells (as on the vast majority of parental cells) and it has been lost by MEC2 cells after several months of culture. The cells have a complex karyotype. The tumour origin of MEC1 and MEC2 has been demonstrated by Southern blot analysis of the IgH loci and by Ig gene DNA sequencing. They use the VH4 Ig family and have not undergone somatic mutations (94.8% homology with germline Ig gene 4-59). Cytofluorographic analysis and RT-PCR reveal that MEC1 and MEC2 overexpress Bcl-2 together with Bax, express large amounts of Bcl-xL and trace amounts of Bcl-xS.
Current Topics in Microbiology and Immunology | 2005
Paolo Ghia; Paola Circosta; C. Scielzo; Antonella Vallario; A. Camporeale; Luisa Granziero; Federico Caligaris-Cappio
Selected microenvironmental stimuli confer to leukemic cells a growth advantage and an extended survival. We aimed at dissecting the differential support provided by the different cellular components of the microenvironment where CLL cells accumulate. To this end we cultured purified CLL cells in vitro in the presence or absence of different accessory cells (stromal cells, autologous T lymphocytes) and/or soluble molecules (IL-4, sCD40L) and assessed the leukemic cell response in terms of cell viability and chemoattracting capacity. The results indicate that both T lymphocytes and stromal cells are involved in sustaining the survival of leukemic B cells, but indicate that their support is different in terms of time of onset and duration. T cells have a short-term support activity while stromal cells provide long-term support.
Journal of Experimental Medicine | 2008
Charlotte Rolny; Lorena Capparuccia; Andrea Casazza; Massimiliano Mazzone; Antonella Vallario; Alessandro Cignetti; Enzo Medico; Peter Carmeliet; Paolo M. Comoglio; Luca Tamagnone
Semaphorins are a large family of evolutionarily conserved morphogenetic molecules originally identified for their repelling role in axonal guidance. Intriguingly, semaphorins have recently been implicated in cancer progression (Neufeld, G., T. Lange, A. Varshavsky, and O. Kessler. 2007. Adv. Exp. Med. Biol. 600:118–131). In particular, semaphorin 3B (SEMA3B) is considered a putative tumor suppressor, and yet we found that it is expressed at high levels in many invasive and metastatic human cancers. By investigating experimental tumor models, we confirmed that SEMA3B expression inhibited tumor growth, whereas metastatic dissemination was surprisingly increased. We found that SEMA3B induced the production of interleukin (IL) 8 by tumor cells by activating the p38–mitogen-activated protein kinase pathway in a neuropilin 1–dependent manner. Silencing the expression of endogenous SEMA3B in tumor cells impaired IL-8 transcription. The release of IL-8, in turn, induced the recruitment of tumor-associated macrophages and metastatic dissemination to the lung, which could be rescued by blocking IL-8 with neutralizing antibodies. In conclusion, we report that SEMA3B exerts unexpected functions in cancer progression by fostering a prometastatic environment through elevated IL-8 secretion and recruitment of macrophages coupled to the suppression of tumor growth.
Journal of Immunology | 2004
Alessandro Cignetti; Antonella Vallario; Ilaria Roato; Paola Circosta; Bernardino Allione; Laura Casorzo; Paolo Ghia; Federico Caligaris-Cappio
Primary acute myeloid leukemia cells can be induced to differentiate into dendritic cells (DC). In the presence of GM-CSF, TNF-α, and/or IL-4, leukemia-derived DC are obtained that display features of immature DC (i-DC). The aim of this study was to determine whether i-DC of leukemic origin could be further differentiated into mature DC (m-DC) and to evaluate the possibility that leukemic m-DC could be effective in vivo as a tumor vaccine. Using CD40L as maturating agent, we show that leukemic i-DC can differentiate into cells that fulfill the phenotypic criteria of m-DC and, compared with normal counterparts, are functionally competent in vitro in terms of: 1) production of cytokines that support T cell activation and proliferation and drive Th1 polarization; 2) generation of autologous CD8+ CTLs and CD4+ T cells that are MHC-restricted and leukemia-specific; 3) migration from tissues to lymph nodes; 4) amplification of Ag presentation by monocyte attraction; 5) attraction of naive/resting and activated T cells. Irradiation of leukemic i-DC after CD40L stimulation did not affect their differentiating and functional capacity. Our data indicate that acute myeloid leukemia cells can fully differentiate into functionally competent m-DC and lay the ground for testing their efficacy as a tumor vaccine.
British Journal of Haematology | 1999
Antonella Vallario; Marco Chilosi; Fausto Adami; Licia Montagna; Silvia Deaglio; Fabio Malavasi; Federico Caligaris-Cappio
Multiple myeloma (MM) plasma cells (PC) are CD38+. A ligand for CD38 is the adhesion molecule CD31. By flow cytometry and immunocytochemistry we have investigated whether malignant PC co‐express CD38 and CD31. All 68 patients studied were CD38+. 14/14 monoclonal gammopathies of undetermined significance (MGUS) and 39/39 plasmacytic MM patients co‐expressed CD38 and CD31 at high density. Only 1/11 plasmablastic MM and 1/4 plasma cell leukaemias (PCL) expressed CD31. These data indicated that PC malignancies co‐expressed high levels of both CD38 and its ligand CD31, with the exception of plasmablastic MM and PCL.
Human Gene Therapy | 2009
Paola Circosta; Luisa Granziero; Antonia Follenzi; Elisa Vigna; Stefania Stella; Antonella Vallario; Angela Rita Elia; Loretta Gammaitoni; Katiuscia Vitaggio; Francesca Orso; Massimo Geuna; Dario Sangiolo; Maja Todorovic; Claudia Giachino; Alessandro Cignetti
We investigated the possibility of introducing exogenous T cell receptor (TCR) genes into T cells by lentiviral transduction, without prior stimulation of endogenous TCR with anti-CD3. TCR transfer is used to impose tumor antigen specificity on recipient T cells, but sustained activation required for retroviral transduction may affect the clinical efficacy of engineered T cells. Cytokine stimulation makes T cells susceptible to lentiviral transduction in the absence of TCR triggering, but this advantage has never been exploited for TCR transfer. Autoimmune diseases are a source of high-affinity TCRs specific for self/tumor antigens. We selected, from a patient with vitiligo, a Mart1-specific TCR based on intrinsic interchain pairing properties and functional avidity. After lentiviral transduction of human peripheral blood mononuclear cells, preferential pairing of exogenous alpha and beta chains was observed, together with effective recognition of Mart1(+) melanoma cells. We tested transduction efficiency on various T cell subsets prestimulated with interleukin (IL)-2, IL-7, IL-15, and IL-21 (alone or in combination). Both naive and unfractionated CD8(+) T cells could be transduced without requiring endogenous TCR triggering. IL-7 plus IL-15 was the most powerful combination, allowing high levels of transgene expression without inducing T cell differentiation (34 +/- 5% Mart1-TCR(+) cells in naive CD8(+) and 16 +/- 6% in unfractionated CD8(+)). Cytokine-prestimulated, Mart1-redirected naive and unfractionated CD8(+) cells expanded better than CD3-CD28-prestimulated counterparts in response to both peptide-pulsed antigen-presenting cells and Mart1(+) melanoma cells. This strategy allows the generation of tumor-specific T cells encompassing truly naive T cells, endowed with an intact proliferative potential and a preserved differentiation stage.
Experimental Hematology | 2003
Alessandro Cignetti; Antonella Vallario; Ilaria Roato; Paola Circosta; Giuliana Strola; Cristina Scielzo; Bernardino Allione; Lucia Garetto; Federico Caligaris-Cappio; Paolo Ghia
OBJECTIVE The mechanisms regulating the trafficking of leukemic myeloid blasts are poorly understood. A differential expression of chemokines and chemokine receptors might account for some aspects of the pattern of invasion and accumulation of leukemic cells. We aimed at defining the pattern of chemokine and chemokine receptor expression of acute myeloid leukemia (AML) blasts in comparison with their putative normal cell counterparts. PATIENTS AND METHODS Twenty-five cases of AML were analyzed by flow cytometry for the expression of several chemokine receptors and by RT-PCR for the expression of relevant chemokines. For selected chemokines, the production was confirmed by ELISA. AML blasts were also assessed for their migration capacity in response to autologous supernatants and recombinant chemokines. RESULTS Undifferentiated AML (MO-M1 and some M2) express only CXCR4 on their surface and produce mainly inflammatory chemokines, resembling normal CD34+ progenitors. More differentiated AML (M4-M5 and some M2) have a more diversified receptor repertoire and, besides CXCR4, express the receptors for inflammatory chemokines and produce both constitutive and inflammatory chemokines, resembling resting and activated monocytes. In particular, M4-M5 blasts produce MCP-1 and MIP-3alpha and also express their specific receptors (CCR2 and, to a lesser extent, CCR6) and migrate in vitro in response to MCP-1 and MIP-3alpha and to their own supernatant. A significant correlation between extramedullary involvement and coexpression of MCP-1/CCR2 was found. CONCLUSIONS These data suggest that chemokines and their receptors segregate within the different FAB subtypes and, by allowing cross-talk among members of the malignant clone, might help to explain some aspects of the pattern of invasion in AML with monocytic differentiation.
Clinical Immunology | 2008
Giuseppe Guida; Antonella Vallario; Stefania Stella; Monica Boita; Paola Circosta; Sara Mariani; Giuseppina Prato; Enrico Heffler; Roberta Bergia; Antonino Sottile; Giovanni Rolla; Alessandro Cignetti
Churg Strauss Syndrome (CSS) is a systemic vasculitis in which oligoclonal T cell expansions might be involved in the pathogenesis. Combined analysis of TCR-Vbeta expression profile by flow cytometry and of TCR gene rearrangement by heteroduplex PCR was used to detect and characterize T cell expansions in 8 CSS patients, 10 asthmatics and 42 healthy subjects. In all CSS patients one or two Vbeta families were expanded among CD8+ cells, with an effector memory phenotype apt to populate tissues and inflammatory sites. Heteroduplex PCR showed the presence of one or more clonal TCR rearrangements, which reveals monoclonal or oligoclonal T cells subpopulations. After purification with a Vbeta specific monoclonal antibody, each CD8+/Vbeta+ expanded family showed a single TCR rearrangement, clearly suggestive of monoclonality. All CD8+ expansions were detectable throughout the disease course. TCR-Vbeta expanded or deleted populations were not observed in asthmatic patients. Clonal CD8+/Vbeta+ T cell expansions might be useful as a disease marker.
Current Topics in Microbiology and Immunology | 1999
Alda Alfarano; Paola Circosta; Antonella Vallario; C. Camaschella; S. Indraccolo; A. Amadori; Federico Caligaris-Cappio
B-chronic lymphocytic leukemia (B-CLL) is an accumulative disease of resting CD5+ B lymphocytes that present a number of distinctive features including the expression of faint to virtually undetectable amounts of monoclonal surface immunoglobulins (sIg), an unusual kinetic hyporesponsiveness, an extended cell survival due to defective apoptosis and a failure to present soluble and allo antigens (1). It is conceivable that abnormalities of the B cell receptor (BCR) may play a prominent role in causing these functional anomalies. The BCR of mature B cells is a multimeric complex formed by the slg homodimer and the noncovalently bound heterodimer Igα/Igs (CD79a/CD79b) encoded by the mb-1 and the B29 genes (2,3). CD79a and CD79b have an extracellular part that forms an Ig-like domain and binds to slg, a transmembrane and a cytoplasmic domain (4). The heterodimer, which is both essential and sufficient for Ig to reach the membrane (2–5), is the signal transducing unit of the BCR (6–8). CD79a and CD79b function synergistically to induce the apoptosis mediated via the BCR (9), influence Ag internalization and increase the efficiency of Ag presentation (10). RNA truncated forms (ΔCD79a and ΔCD79b) which arise by alternative splicing have been described in a variety of human B cells and B cell lines (11,12). ΔCD79a lacks a portion of the extracellular domain encoded by exon 2(13) and ΔCD79b lacks the entire extracellular Ig-like domain encoded by exon 3(11).
Blood | 1999
A. Alfarano; S. Indraccolo; Paola Circosta; S. Minuzzo; Antonella Vallario; R. Zamarchi; A. Fregonese; F. Calderazzo; A. Faldella; M. Aragno; Clara Camaschella; A. Amadori; Federico Caligaris-Cappio